Rare disease focus Target collaborations and licensing discussions with biotech firms and patient advocacy groups focused on pediatric metabolic disorders, highlighting HemoShear’s proprietary human liver disease models and potential to accelerate drug discovery for MMA, PA, and similar conditions.

Clinical pipeline potential Position HemoShear’s HST5040 and other target discovery programs as early-stage, high-uncertainty assets with the potential to de-risk by using patient-derived liver models, appealing to strategic partners seeking novel mechanisms for rare metabolic diseases.

Strategic partnerships Leverage past collaborations (Horizon Therapeutics, OpenBench) to attract co-development or technology licensing opportunities that combine OpenBench screening with HemoShear’s disease models to accelerate lead discovery for hepatic, vascular, or tumor biology indications.

Funding readiness Highlight the company’s recent debt financing and ongoing venture-style funding to support early-stage research; target investors and grant programs focused on rare diseases and pediatric therapeutics, emphasizing runway for pipeline progression.

Market positioning Differentiate from peers by offering access to unique human disease models that emulate pediatric metabolic defects; pursue collaborations with CROs, biotech partners, and pharma companies seeking differentiated preclinical assets with higher translational relevance.